Clinical trials: Pancreatobiliary Cancers
Ampullary Adenocarcinoma
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype.
- Trial name
- ADAPTA (NCT06068023)
- Testing
- Folfirinox, Capox
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Pancreatic Cancer, Cholangiocarcinoma
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
Based on the cell free nucleic acid analysis information of blood samples, the results of microbiome and metabolite analysis of stool and urine samples of pancreatic cancer and bile duct cancer patients, the clinical correlations…
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT05596370
- Testing
- cell free DNA in blood and urine, metabolite/microbiome in urine and stool
- Where
- 2 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic